by Raynovich Rod | Mar 30, 2018 | Biopharmaceuticals
2018 Large Cap Biopharmaceuticals – Performance Compared to ETFs It has been a rough start for large cap biopharmaceutical stocks but the ETFs (FBT) and (XBI) still outperformed the SPY YTD and over 12 months. Most Individual stocks lagged unless you owned...
by Raynovich Rod | Mar 29, 2018 | Biopharmaceuticals
4/2/18 12:30P Update Biotechs break through 2018 support levels with XBI now needs to hold December lows at $80. IBB at double bottom hit in November/December at $102 level. Watch Mid-Cap list below for sector weakness. ============== Biotech Bull Market Is Intact...
by Raynovich Rod | Mar 25, 2018 | Biopharmaceuticals, Macro
Sell-Off Gets Scary–NASDAQ Futures Still Down at 1:30A EDT 3/28 Double Bottom -Double Top on XBI and Testing February Lows at $87 Another Sell-Off=Tuesday Movers 3/27/18 Large Caps % Up-NONE FBT Down 3.23%, IBB Down 2.77% to $105.12, QQQ down 3.24%, XBI down...
by Raynovich Rod | Mar 20, 2018 | Biopharmaceuticals
Update-2…3/22 ABBV News Kills Momentum of Biotech Stocks 12:30P EDT Abbvie (ABBV) down 13.5 % on disappointing results on blood cancer drug. The big issue is that the drug was recently acquired for $5.8B from Stemcentrx back in 2016. The Company will not seek...
by Raynovich Rod | Mar 19, 2018 | Biopharmaceuticals, Macro
Update-1… 3/19. Close is off the lows for Biotech Indices QQQ gap down to $167.10 also at SMA 50 XBI at SMA 50 bottom of channel at $91.89 XLV at $84 approaching February lows of $81 It is very difficult to find news or trends that can help us navigate this...
by Raynovich Rod | Mar 14, 2018 | Biopharmaceuticals
Update-1 …March 18- Market jittery on potential global trade war, rising interest rate concerns and political risk. Also Sales to U.S. retailers fell 0.1% in February a 3 month slide. Biotechs are in a risk-off mode with a weak tape. Dow down 0.47%, NASDAQ down...
by Raynovich Rod | Mar 6, 2018 | Biopharmaceuticals
Update-1 March 10… Broad Rally Continues Through The Week QQQ Up 4.3% IBB up 4.3% XBI up 4.8% Gene Editing Stocks Surge Biotech stocks soared along with the market as fear about interest rates, tariffs and global politics subsided helped considerably by economic...